Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.42 |
| ▸ | RAF1 | P04049 | 9/20 | 0.42 |
| ▸ | LCK | P06239 | 6/20 | 0.40 |
| ▸ | LYN | P07948 | 6/20 | 0.40 |
| ▸ | SRC | P12931 | 6/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.40 |
| ▸ | INSR | P06213 | 5/20 | 0.40 |
| ▸ | HCK | P08631 | 5/20 | 0.40 |
| ▸ | ARAF | P10398 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589488 | 0.94 | BRAF (0.47) | BRAFRAF1LCKLYNSRC | |
| SCHEMBL3590950 | 0.89 | BRAF (0.40) | BRAFRAF1LCKLYNSRC | |
| SCHEMBL3583837 | 0.89 | LCK (0.44) | BRAFRAF1LCKLYNSRC | |
| SCHEMBL3580341 | 0.89 | BRAF (0.46) | BRAFCSF1R | |
| SCHEMBL3589393 | 0.87 | LCK (0.48) | BRAFRAF1LCKLYNSRC | |
| SCHEMBL9928651 | 0.87 | LCK (0.43) | BRAFRAF1LCKLYNSRC | |
| SCHEMBL3590408 | 0.86 | BRAF (0.47) | BRAFLCKLYNSRCKDR | |
| SCHEMBL3589191 | 0.86 | LCK (0.45) | BRAFRAF1LCKLYNSRC | |
| SCHEMBL3588170 | 0.86 | KDR (0.42) | BRAFRAF1LCKLYNSRC | |
| SCHEMBL14219021 | 0.85 | KDR (0.49) | BRAFLCKLYNSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | claimed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| EP-2010542-A2 | 4,5-DIHYDRO-[1,2,4]TRIAZOLO[4,3-F]PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | BRAF 11/4885RAF1 10/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.